Market Research Blog – Page 10847 – New Product Development

Auto-Injectors Market Key Players : Sanofi, Pfizer, Inc, Becton, Dickinson and Company, Mylan N.V., Novartis AG

Anaphylactic shock is the most common chronic disease in Europe and North America region. Allergy UK says, approximately 20% of patients struggle with anaphylactic reaction in Europe. Anaphylactic shock requires adrenaline auto injector devices to be treated. Adrenaline auto injectors are sold under various brands, such as Emerade, Epipen and Jext in the UK. The global auto injectors market was valued at US$ US$ 1,700 Mn, in terms of value, in 2016, according to the latest research by Future Market Insights (FMI). The report on auto injectors further projects significant growth potential with average year-on-year growth rate of 15.1% through 2026.

Auto injectors are an effective mode of administration for intramuscular drugs. User friendly attributes of auto injectors reduce the burden of carrying conventional needles and syringes. However, limited awareness regarding proper use of auto injectors and high price of branded products are some of the important factors curbing the adoption of auto injector devices in emergency applications.

Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1642

Based on research conducted by the McGill University’s Health Centre Research Institute, allergic patients procuring EpiPen for emergency are not actually using the product as quickly as they should. Further, a number of patients visiting the emergency department due to severe anaphylaxis reaction are already administered epinephrine, says the Journal of Allergy and Clinical Immunology.

Failure to use auto injectors at the right time is mainly due to lack of knowledge about signs of anaphylaxis. Such lack of awareness about the disease and product creates significant challenges, in terms of product adoption, for the manufacturers. Apart from higher pricing, limited shelf life of auto-injector pen & under supply of products (Ex. EpiPen) are the major challenges hindering the patient preference for auto injectors in emergency.

Increasing innovations in materials and device functions of auto-injectors are driving the expansion of the auto injector market. In September 2015, Bayer HealthCare reported the launch of Betaconnect- an electronic auto injector for the treatment of relapsing-remitting multiple sclerosis (RRMS). This auto injector offers complete drug dosage for improved compliance and potentially reduce the overall cost. The SHL Group offers a variety of auto injectors that can accommodate changes in injections, such as larger volumes, high viscosity and others. The auto-injector manufacturers are focusing on improving the functionality of auto-injectors to improve disease management and treatment.

Fierce competition in the auto injectors market due to the patient protection act has created an oligopolistic market environment. As a result, brands, such as EpiPen auto-injector, BD Physioject disposable auto injector, etc., have maintained their ranks in the market. However, recent patient expiration and increasing pressure from government bodies will led to reduction in auto injector prices and thus, reduce the profitability for branded manufacturers.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1642

Generic auto injectors are expected to present high growth opportunities for investors due to growing support from private insurance providers. Insurance services providers are dropping coverage on highly priced auto injectors and covering newly launched half priced generics. Overall revenue from pre-filled syringes is expected to grow during the forecast period due to rising need for targeted and sustained drug delivery. New entrants must comprehensively study the Auto Injectors market to penetrate and sustain in the price sensitive market. The study of the market scenario will provide insights about the business opportunities

FMI has segmented the global auto injector market by product type, indication, distribution channel & regions. In terms of revenues, pre-filled auto injectors will hold substantial market share over the forecast period. On the contrary, the Fillable auto-injectors segment will exhibit limited investment opportunities, in terms of revenue, through 2026.

This FMI report covers some of the key companies operating in the auto injectors market, such as

Sanofi, Pfizer, Inc.,
Becton,
Dickinson and Company,
Mylan N.V.,
Novartis AG,
Janssen Global Services,
LLC,
Antares Pharma,
Amgen Inc.
Bayer AG, & Eli Lilly and Company.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/1642

Key Segment

based on product type

Prefilled Auto-injectors
Fillable auto-injectors

based on distribution channel

Traditional sales channels
hospital pharmacies
retail pharmacies

based on regions

North America
Latin America
Europe
Asia Pacific Excluding Japan
Japan
MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Magnetic Resonance Imaging (MRI) Contrast Agents Market is projected to grow 1.23 Bn by the end of 2029

[240 Pages Report] A recent market study published by Future Market Insights (FMI) on the magnetic resonance imaging (MRI) contrast agents market offers global industry analysis for 2014-2018 and opportunity assessment for 2019-2029. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the magnetic resonance imaging contrast agents market, growth prospects of the market are obtained with maximum precision.

The report features unique and salient factors that may make a huge impact on the development of the magnetic resonance imaging contrast agents market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the MRI contrast agents market in the coming years. The report provides detailed information about the current and future growth prospects of the magnetic resonance imaging contrast agents market in the most comprehensive way for better understanding of readers.

Data Points	Market Insights
Market Value 2022	U.S. $ 910.9 Mn
Market Value 2029	U.S. $ 1.23 Bn
CAGR 2022-2029	4.4%
Share of top 5 countries	60.8%

Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11023

Magnetic Resonance Imaging (MRI) Contrast Agents Market : Segmentation

FMI’s study on the magnetic resonance imaging contrast agents market offers information divided into three important segments— product type, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

By Product

Paramagnetic Contrast Agents
- Extracellular Fluid (ECF) Agents
- Blood Pool Contrast Agents (BPCAs)
- Organ-specific Agents
Superparamagnetic Contrast Agent

End User

Hospitals
Ambulatory Surgical Centers
Diagnostic Centers

Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
MEA

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-11023

Chapter 1 – Executive Summary

The report commences with the executive summary of the MRI contrast agents market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the magnetic resonance imaging contrast agents market, as well as the key trends impacting the market.

Chapter 2 – Market Overview

Readers can find detailed taxonomy, definition of the magnetic resonance imaging contrast agents market, and the key inclusions and exclusions in this chapter, which help readers understand basic information about MRI contrast agents.

Chapter 3 – Key Market Trends

This section highlights the key trends impacting the magnetic resonance imaging contrast agents market, which will help readers understand the current trends and their impact on market growth.

Chapter 4 – Key Success Factors

In this chapter, the reader can get information about the parent market of MRI contrast agents market. Novel use cases, product adoption by region, product USPs, number of scans by country, and how combination imaging modalities will enhance medical imaging.

Chapter 5 – Global Magnetic Resonance Imaging Contrast Agents Market Volume (In Liters) Analysis 2014-2018 and Forecast, 2019-2029

This section explains the current and future market volume (In Liters) projections and the growth trend. Readers can also get knowledge the current installed base of MRI Units, by region/ country and historical market volume (In Liters) of global magnetic resonance imaging (MRI) contrast agents market.

Chapter 6 – Global Magnetic Resonance Imaging Contrast Agents Market – Pricing Analysis

The report covers the pricing analysis of the market on the basis of region and other attributes in this chapter. It will help the reader find comparative analysis of product pricing across different regions of the globe.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/11023

Chapter 7 – Global Magnetic Resonance Imaging Contrast Agents Market Value (US$) Analysis 2014-2018 and Forecast, 2019-2029

This section explains the global market value analysis and forecast for the MRI contrast agents market during the forecast period of 2019-2029. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029).

About FMI:

Oxygen Therapy Equipment Market to reach US$ 6.4 Billion in 2032

[322 Pages Report] According to a recent study done by Future Market Insights, the oxygen therapy equipment market is expected to reach US$ 6.4 Billion by 2032, up from US$ Oxygen Therapy Equipment Market billion in 2022, expanding at a high CAGR of 7.4%. This study explains that the Chronic respiratory diseases affect more than 1 billion people, globally, as per the Global Asthma report, 2018. COPD, with tobacco smoking as its root cause, has affected a significant part of the world population, as per the World Health Organization. These factors are expected to accelerate the growth of the Oxygen Therapy Equipment Market during the forecast period.

The advent of the technologically advanced oxygen source and delivery devices, which offers efficient patient care, is expected to boost the industry. These advancements include flow regulating devices, sensors, and conjunction of delivery devices with pulse dose meters. The adoption of O₂ therapy is increasing owing to the potential benefits such as controlled flow, efficient dosing, faster response rates, and greater durability & reliability. The aforementioned factors are anticipated to propel industry expansion.

Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15011

In addition, rising popularity and adoption of on-demand and continuous Portable Oxygen Concentrators (POC) in a wide range of applications such as emergency medicine is also expected to fuel the demand in the forthcoming years. This surge is attributable to global competitors entering the market, demand for the portable technology by consumers, and the clinical urgency for greater mobility support for the geriatric population. The business is anticipated to increase owing to continuous innovation and resulting in more efficient units and reduced prices.

Increasing incidences of chronic respiratory diseases coupled with rising demand for home healthcare are the major drivers of the market. This can be ascribed to increasing geriatric population suffering from various kinds of chronic diseases in which oxygen therapy or oxygen support is required. Additionally, increasing levels of air pollution, smoking habits of population especially youth, among others have significantly contributed to an increase in the prevalence of respiratory diseases, thereby increasing the demand for oxygen therapy equipment.

As per the National Institutes of Health (NIH), nearly 12 million adults have been diagnosed with Chronic Obstructive Pulmonary Disease (COPD) in the U.S. and 120,000 people die each year. According to the data published by the Global Asthma Network (GAN), asthma affects nearly 334 million people worldwide.

North America dominates the oxygen therapy equipment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing awareness about the benefits associated with oxygen therapy in hospitals and increasing number of end-users in this region.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-15011

Key Takeaways from the Market Study

Global Oxygen Therapy Equipment Market was valued at US$ 3.1 Million by 2022-end
The US to account for the highest value share of US$ 2.4 Billion of global market demand for Oxygen Therapy Equipment Market in 2032
From 2015 to 2021, Oxygen Therapy Equipment demand expanded at a CAGR of 7%
By Product, the Oxygen Source Equipment category constitutes the bulk of Oxygen Therapy Equipment Market with a CAGR of 2%.
By Portability, the Stationary Devices segment dominates the Oxygen Therapy Equipment Market with a CAGR of 8%.

“The rising popularity and adoption of on-demand and continuous Portable Oxygen Concentrators (POC) in a wide range of applications such as emergency medicine is also expected to fuel the demand over the forecast period,” remarks an FMI analyst.

Competitive Landscape

Players in the global Oxygen Therapy Equipment Market focus on expanding their global reach through various strategies, such as; partnerships, collaborations, and partnerships. The players are also making a significant investment in R&D to add innovations to their products which would help them in strengthening their position in the global market. Some of the recent developments among the key players are:

In July 2021, Belluscura (BELL) had signed a third distribution deal and first agreement with a durable medical equipment provider, for its X-PLO2R™ portable oxygen concentrator portfolio. The durable medical equipment (“DME”) has multiple stores in several states and an online store. Meanwhile, the third distributor has issued its first purchase order with anticipated delivery of the X-PLO2R™ portable oxygen concentrator expected in less than ninety days.
In June 2020, Armstrong Medical introduced the second generation FD140i, an improved dual therapy flow driver with an easier transition from CPAP to HFOT.
In August 2019, OxyGo LLC announced the launch of their new six flow setting, Bluetooth enabled POC. At only 4.7 pounds, and with 6 flow settings, the OxyGo NEXT offers the highest oxygen output per pound of weight of any portable oxygen concentrators currently on the market. Created to meet the needs of oxygen therapy patients and home medical equipment providers – for use at home, away, and for travel. OxyGo NEXT will allow healthcare providers to improve patient outcomes through a new wireless connectivity platform using Bluetooth technology.
In October 2018, Resmed launched CPAP mask-Airlift f30i for Hospitals and Respiratory Care Physicians in the US.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-15011

Know More about What the Oxygen Therapy Equipment Market Repost Covers

Future Market Insights offers an unbiased analysis of the global Oxygen Therapy Equipment Market, providing historical data for 2015-2021 and forecast statistics from 2022-2032.

To understand opportunities in the Oxygen Therapy Equipment Market, the market is segmented on the basis of product, portability, and application across five major regions.

Key Players :

Philips Healthcare
Linde Healthcare
Chart Industries, Inc.
Invacare Corporation
Becton, Dickinson and Company
Smiths Medical
Drägerwerk AG & Co. KGaA
Teleflex Incorporated
Fisher & Paykel Healthcare Corporation Limited
Taiyo Nippon Sanso Corporation, Inogen, Inc.
Heinen + Löwenstein GmbH & Co. KG
DeVilbiss Healthcare
Essex Industries, Inc.
HERSILL, S.L.
Weinmann Emergency Medical Technology GmbH + Co. KG
Messer Medical Austria GmbH
TECNO-GAZ S.p.A, HUM – Gesellschaft für Homecare und Medizintechnik mbH
medicap homecare GmbH
GCE Holding AB

Key Segments Covered in the Oxygen Therapy Equipment Market Report

Oxygen Therapy Equipment Market by Product:

Oxygen Source Equipment
Oxygen Therapy Equipment for Cardiovascular & Thoracic Surgeries
- Oxygen Concentrators
- Liquid Oxygen
- Oxygen Cylinders
Oxygen Delivery Devices
- Oxygen Masks
- Nasal Cannulas
- Venturi Masks
- Non-Rebreather Masks
- Bag-Valve Masks
- Other Oxygen Delivery Devices

Oxygen Therapy Equipment Market by Portability:

Stationary Oxygen Therapy Equipment Devices
Portable Oxygen Therapy Equipment Devices

Oxygen Therapy Equipment Market by Application:

Oxygen Therapy Equipment for COPD
Oxygen Therapy Equipment for Asthma
Oxygen Therapy Equipment for Cystic Fibrosis
Oxygen Therapy Equipment for Respiratory Distress Syndrome
Oxygen Therapy Equipment for Pneumonia
Oxygen Therapy Equipment for Other Diseases

About FMI:

Clinical Oncology Next-generation Sequencing Market is estimated to be worth around US$ 449.4 Million in 2022

Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing. It is an advanced and faster method of sequencing. Clinical oncology next-generation sequencing includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall market.

North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.

Synthesis Sequencing Technology to Hold a Major Market Value Share

Based on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9543

Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the “sequencing by synthesis” principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which also known as DNA is sequencing.

There are various applications associated with clinical oncology next-generation treatment market. They include whole tumor genome sequencing, whole tumour exome sequencing, targeted tumour genome profiling, tumour transcriptome sequencing, tumour-normal comparisons, and other applications. Targeted tumor genome profiling is expected to hold a large share of the clinical oncology next-generation treatment market.

On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organisations, diagnostic laboratories, and others. Clinical research laboratories are expected to hold a large revenue share in the clinical oncology next-generation sequencing market.

Apart from the factors driving the clinical oncology next-generation sequencing market, there are few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with the establishment of sequencing platforms, low quality of outsourcing services, and inadequate availability of sequencing platforms in some regional markets.

On the other hand, increasing biomedical research using clinical oncology, increasing government funding for life science projects, substantial decline in the prices of sequencing, and technological advancements in the field of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-9543

Tier 1 Companies Hold Nearly 3/5th Share of Global Market Value

The report tracks some of the key companies operating in the clinical oncology next-generation sequencing market such as QIAGEN N.V., Thermo Fisher Scientific., Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd., Takara Bio, Inc., Illumina Inc., PerkinElmer Inc.and Agilent Technologies, Inc. Thermo Fischer Scientific, Oxford Nanopore Technologies Ltd., and Illumina are expected to hold a signficant share of the clinical oncology next-generation sequencing market. These first tier companies hold a share of approximately 60% in the clinical oncology next-generation sequencing market.

CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET TAXONOMY

The global clinical oncology next generation sequencing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

• Sequencing Platforms
• Sequencing Products
• Kits and Reagents
• Services

By Technology

• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing (SBS)
• Real Time Sequencing (SMRT)
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-9543

By Application

• Whole Tumor Genome Sequencing
• Whole Tumor Exome Sequencing
• Targeted Tumor Genome Profiling
• Tumor Transcriptome Sequencing
• Tumor-normal Comparisons
• Others

By End User

• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories
• Others

About FMI:

Connected Drug Delivery Devices Market is anticipated to reach US$ 1.6 Billion by 2028

[228 Pages Report] According to the analyst of Future Market Insights (FMI), the leading manufacturers of connected drug delivery devices are focusing collaboration with the software companies to assess the cloud data system in their devices.

The market for connected drug delivery devices is foreseen to witness a stellar growth rate of 25.6% from 2013 to 2028 rising to a valuation of US$ 1,304.7 Mn from US$ 132.2 Mn in 2022.

Moreover, it helps the manufacturer to launch the product more conveniently and to enhance their distribution channel. Manufacturers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly.

The companies operating in the global connected drug delivery devices market are OPKO Health Inc., Bayer AG, 3M Company, West Pharmaceutical Services, Inc., and Teva Pharmaceutical Industries Ltd., among others.

Rapidly evolving technologies, for instance, cloud-based computing models, are enabling the healthcare industry towards a transition to a new architecture.

Cloud technology along with advances in mobility and telepresence solutions is expected to create new unwired business models capable of providing healthcare anywhere.

The use of cloud technology will increase, aided by the proliferation of mobile health applications to collect and send vital signs from wireless and wired remote patient and personal health monitoring devices. Cloud-based platforms and new IT service models will fundamentally change the healthcare business equations and create opportunities for new players to enter the industry.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-2755

Growing Demand for Injectable Drug Delivery to Aid Market Growth

The rising preference for injectable drug delivery is anticipated to drive the market for sterile drugs globally. Self-administration of drugs through usage of pre-filled syringes is one of the ways that can help patients to save the fees given to a caregiver. There is an increased demand for large molecule drugs in pre-filled syringes as compared to small molecule drugs in pre-filled syringes

Following this opportunity, the manufacturers are expected to cash in on profits through introduction of smart injectable drug delivery mediums among their portfolio. The progress is expected to be more prominent in the allergic reactions (Anaphylaxis) indication segment. Further, an upsurge in the number of large molecule drugs that need to be manufactured in injectable format is expected to fuel the growth of the market. Likewise, data generated by bioavailability studies is proving to present a definitive relation between pharmacodynamics and pharmacokinetics for such sterile drugs, which is also expected to offer support to the growth of the market.

Mobile applications are also being used for the treatment of patients suffering from Alzheimer, Diabetes, COPD or Asthma. Mobile applications with the use of GPS help to track the patient location. If the patient is travelling away from the home, the caretaker can track the exact location of the patient and also track the consumption of dosage by using mobile application. Most of these applications have been developed for the cloud. Placing the wireless solution on a cloud storage system helps with connectivity issues and makes it easier to communicate across different information regimes.

Limited Knowledge and Adoption Rate among Patients to Hinder Growth Rate

The deployment of connected drug delivery devices is not yet widely promoted within the public health system. This is attributed to the high cost of the product, limited reimbursement, and dearth of awareness among the patients regarding the technology. Moreover, complexity and limited availability of the device further reduces penetration. For instance, interpretation of insulin delivery trend for analysis, is considered to be useful however, because of the complicated user interface, the patients cannot interpret them smoothly. As per the current scenario, such obstacles might directly have an adverse effect on the overall growth of the connected drug delivery devices market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2755

Key Segments of Connected Drug Delivery Devices Industry Survey Connected Drug Delivery Devices Market by Product Type:

Inhalation Devices
Injectable Devices
- Handheld Injectable Devices
- Wearable Injectable Devices

Connected Drug Delivery Devices Market by End User:

Hospitals
Clinics
Home Care

Connected Drug Delivery Devices Market by Application:

Anaphylaxis
Cardiovascular
Diabetes
Hormone Replacement
Others

Connected Drug Delivery Devices Market by Technology:

Bluetooth Drug Delivery Devices
Near Field Communication Drug Delivery Devices

Connected Drug Delivery Devices Market by Region:

North America Connected Drug Delivery Devices Market
Latin America Connected Drug Delivery Devices Market
Europe Connected Drug Delivery Devices Market
East Asia Connected Drug Delivery Devices Market
South Asia & Pacific Connected Drug Delivery Devices Market
Middle East & Africa (MEA) Connected Drug Delivery Devices Market

About FMI:

Female Pelvic Implants Market rising at a CAGR of 2.8% through the end of 2031

According to a recent report by Future Market Insights (FMI), rising prevalence of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) is expected to boost the growth opportunities for female pelvic implants market. The market is set to reach a valuation of US$ 245 Mn in 2021, rising at a CAGR of 2.8% through the end of 2031.

According to the American Urological Association (AUA/SUFU), the incidence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The incidence of stress urinary incontinence is high in women with poor or weakened pelvic supports. This disease affects the lives of women to a great extent and is widespread in the older population.

Increasing incidence of vaginal disorders among aged women coupled with the non-availability of other treatment options for SUI and POP will continue increasing the demand in the female pelvic implants market. According to the U.S. FDA, the number of women who have POP is estimated to surge by 46%, to 4.9 million, by 2050.

Get Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3422

However, the low rate of efficacy after pelvic implantation and the problems of pelvic organ prolapse are hampering the growth of the female pelvic implants market. COVID-19 is anticipated to have a moderately negative impact on the female pelvic implants market due to implementation of lockdown. Supplies and demand were jolted by the massive spread of the infection, which staggered the growth of the female pelvic implants market.

Key Takeaways from Female Pelvic Implants Market Study

Vaginal sling/tapes demand is anticipated to gain maximum revenue share of more than 68%, rising at an expected CAGR of 2.5% owing to the high demand to treat stress urinary incontinence.
Hospitals followed by ambulatory surgical centers are leading users of female pelvic implants growing owing to the rising number of POP and SUI patients.
The U.S. accounts for more than 83% of the North America market, driven by the high incidence of pelvic organ prolapse.
The U.K.is a leading market in Europe. It is expected to account for nearly 13% of demand registered in Europe by 2031. Implementation of government funded awareness programs will remain a chief growth driver.
Over 30% of the South Asia market is held by India. Growth in the country is propelled by significant investments in the expansion of healthcare sector.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3422

Post-Marketing Surveillance of Approved Devices Influencing Female Pelvic Implants Demand

An increasing number of manufacturers are continuing to sell their products in the global market despite restrictions by law. After the FDA reclassification of vaginal mesh implants from Class II to Class III medical devices, the FDA has advised 33 manufacturers to conduct 3-year studies to assess impacts of organ damage and other complications of mesh implants.

After assessing the risks, manufacturers can reintroduce their devices and can get pre-market approval from the FDA. This allows manufacturers to re-launch the mesh implants, which is expected to come into the market by 2022.

Who is Winning?

Key players in the market are focusing on strategic collaborations, acquisitions, and expansion. Furthermore, product launches, agreements and research sponsorships are key strategies adopted by manufacturers to strengthen their product portfolios in the female pelvic implants market.

For instance, Coloplast acquired Nine Continents Medical, Inc. in November 2020 and aimed to expand its medical device product portfolio.

The FDA, in 2019 completed its broad evaluation of data associated with the resin used in the production of Boston Scientific’s vaginal mesh through which, the US federal law limits these devices to sale by order of a surgeon.

Want More Insights?

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Female Pelvic Implants Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the Female Pelvic Implants Market on basis of product type [Vaginal Mesh Implants, Vaginal Sling/Tape and Vaginal Graft Implants], Indication [Pelvic Organ Prolapse (POP) and Stress Urinary Incontinence (SUI)]. Based on End User [Hospitals, Ambulatory Surgical Centers and Specialized Clinics] across seven major regions.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-3422

Market Taxonomy Product Type

Vaginal Mesh Implants
Vaginal Sling
Vaginal Graft Implants

Indication

Pelvic Organ Prolapse
Stress Urinary Incontinence

End User

Hospitals
Ambulatory Surgical Centres
Speciality Clinics

Region

North America
Latin America
China
Western Europe
Eastern Europe
APECJ
Japan
MEA

About FMI:

Exosome Diagnostic and Therapeutics Market is expected to reach USD 175.4 million by 2028

The Exosomes Diagnostic and Therapeutic Market is estimated at USD 58.6 million in 2022 and is projected to reach USD 175.4 million by 2028, growing at a CAGR of 20.0% during the forecast period (2022-2028).

Future Market Insights in its recent research report titled “Exosome Diagnostic and Therapeutics Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027)” covers several factors that are influencing the robust growth of the global market. As per this research report, the global exosome diagnostic and therapeutic market is projected to expand at a high CAGR of 23.1% during the period of assessment.

The exhaustive research publication includes key trends, opportunities, threats, growth drivers and challenges that impact the global exosome diagnostic and therapeutics market. Detailed pricing analysis of different exosome diagnostic and therapeutics across key regions is also discussed in the research study. The segmental analysis across North America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Latin America, Japan and Middle East and Africa (MEA) is carried out which is used to track the future projections for a period of ten years, pertaining to value, of the global exosome diagnostic and therapeutics market.

To remain ‘ahead’ of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-6379

Global Market for Exosome Diagnostic and Therapeutics: Underlying Forces Influencing Growth

The growth of global market for exosome diagnostics and therapeutics is influenced by several factors. Increasing need for screening and diagnosis of chronic diseases coupled with high therapeutic potential of exosomes are fuelling the adoption of exosome diagnostics and therapeutics. Moreover, introduction of explicit systems for analysis of proteins specific to exosomes, increasing research and development activities supported by favourable government policies across various regions and increasing popularity of exosome over CTC and ctDNA are expected to trigger the growth of the global market for exosome diagnostic and therapeutics market in the years to follow. On the contrary, lack of standardization and validation requirements for isolation of exosomes is expected to pose hindrances to the growth of the global market. Other factors negatively impacting the market’s growth include heavy investments in research and development and insufficient insurance coverage of costly cancer diagnostic tests.

Segmentation Highlights of the Global Exosome Diagnostic and Therapeutics Market

The global exosome diagnostic and therapeutics market is segmented on the basis of product type, application, end user and region.

In the region category, North America is estimated to be the largest with a high market lucrativeness. This region is expected to grow at a significant CAGR during the forecast period to touch a large market estimation by end of the assessment year, thus leading the global market. Moreover, Asia Pacific excluding Japan (APEJ) is the fastest growing region and is the second largest in terms of adoption and use of exosome diagnostics and therapeutics. APEJ is filled with high growth opportunities and is being targeted by several giants in this sector, such as Thermo Fisher Scientific.

By product type, reagents and kits are gaining high traction owing to increasing use in exosome diagnostics and therapeutics. The reagents and kits segment dominated the market in 2017 and is anticipated to continue with the trend in the coming years. This segment is also expected to expand at a high growth rate during the forecast period. The reagents and kits segment is expected to register a high CAGR of 28.2% throughout the period of forecast. The software segment is the second fastest growing segment spurring the growth of the global market.

In the application category, diagnostic segment is the largest as compared to therapeutics segment and is estimated to touch a value of over US$ 90 Mn by the end of the year of assessment, growing at a significant pace. Therapeutics segment is projected to expand at a CAGR of 29.0% throughout the period of assessment.

With respect to end user, the use of exosome diagnostic and therapeutics is largely observed in diagnostic centres. The diagnostic centres segment is expected to surpass other end user segments with a high market share and growth rate in the coming years.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-6379

Forecast Analysis of the Global Exosome Diagnostic and Therapeutics Market

According to the research report, the global market for exosome diagnostic and therapeutics is expected to grow at a high CAGR to reach an estimate of over US$ 150 Mn by the end of the year of assessment from a value of about US$ 19 Mn in 2017.

Competitive Landscape Shaping the Global Exosome Diagnostic and Therapeutics Market

Manufacturers of exosome diagnostic and therapeutics are focusing to raise capital required for launch of new products or research and development expenses through venture financing. Key companies such as

Thermo Fisher Scientific Inc.
NanoSomix Inc.
NX PHARMAGEN
Capricor Therapeutics Inc.
Exosome Diagnostics Inc.
Exiqon A/S (Aethlon Medical Inc.).
System Biosciences Inc.
Aegle Therapeutics AMS Biotechnology (Europe) Limited
Miltenyi Biotec.

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-6379

Market segmentation

By Product Type

- Instrument
Software
Reagents and Kits

By Application

Diagnostics
Therapeutics

By End User

Hospitals
Cancer Institutes
Diagnostic Centres
Others

By Region

North America
Latin America
Eastern Europe
Western Europe
Asia Pacific excluding Japan
Japan
Middle East and Africa

About FMI:

Pressotherapy Systems Market is projected to expand at a CAGR of 4.1% from 2022-2032

[250 Pages Report] As per Future Market Insights’ latest industry analysis, the global pressotherapy systems market size reached around US$ 174.0 Mn in 2021 and is set to grow at 4.1% CAGR over the forecast period (2022-2032).

Attribute	Key Statistics
Pressotherapy Systems Market Size (2021)	US$ 174.0 Mn
Value-based CAGR 2022-2032	4.1%
Market Share of Top 5 Countries	46.9%

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3668

Due to sedentary lifestyles and an aging population, there has been a rapid surge in diseases like diabetes and peripheral edema. This has resulted in the rising usage of lipo-laser and acoustic wave therapy, which is a major factor accelerating growth in the global pressotherapy systems market.

Physical activity, especially competitive activity, brings about in the human body several detrimental alterations. When muscle cells are damaged, chemicals such as creatine kinase (CK), lactate dehydrogenase, and others are produced, which leads to inflammation.

In such circumstances, there is observed, a decline in performance, accelerated muscle aging, a reduction in range of motion, and the onset of pain in the overloaded area. Eccentric workouts, which involve vigorous exercise that may result in delayed onset muscle soreness, are particularly aggravating to this issue.

Treatments in the fields of physical therapy, such as cold and heat therapy, massage, compression therapy, and electrotherapy, manual therapy, and pharmaceuticals are some of the most often utilized strategies for biological recovery.

Of the aforementioned techniques, compression therapy has received a lot of attention recently, with External Pneumatic Compression (EPC) and Intermittent Pneumatic Compression receiving the most attention (IPC). Pressotherapy is also recognized as IPC.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-3668

Additionally, the establishment of the Lymphedema Framework in the region of Europe honors the efforts of nations like France, Germany, the Netherlands, and Spain that made it possible for local reimbursement of compression garments. The UK Department of Health’s choice to include compression garments for lymphedema on the UK Drug Tariff as of 1 March 2006 was influenced by the formulation of the Lymphedema Framework’s own guidelines.

Thus, owing to the growing incidence of circulation problems and fluid retention, as well as the initiatives taken by the regional governments in promoting product utilization, the market for pressotherapy systems is expected to witness a steady growth rate during the forecast period.

Key Takeaways from Market Study

Based on product, system/pump is the leading segment, holding approximately 9% market value share in 2021.
By end user, specialty clinics segment accounted for the largest share of 64% of the global pressotherapy systems market in 2021 while the medical spas segment is expected to grow at the fastest CAGR of 5% during the assessment period.
North America lead the global pressotherapy systems market with around 2% share in 2021, owing to the high prevalence of chronic diseases in the region.
Europe is expected to remain the second most lucrative market for pressotherapy systems, accounting for around 1% market share value in 2021.
Pressotherapy systems market in East Asia is likely to grow at the fastest CAGR of 5.6% between 2022 and 2032.

“The pressotherapy systems market will expand steadily over the assessment period due to increased consumer awareness of product availability and growing demand for compression therapy in injury cases,” says an analyst of Future Market Insights.

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-3668

Market Competition

Key players in the pressotherapy systems market are involved in new product designs with morphologic technology to better suit the target consumer/patient base. The market for pressotherapy systems is competitive with many players within the compression and wound therapy space.

In January 2019, Baldan Group launched Iridium Eye Pressotherapy.
In May 2019, preliminary data, presented at the Symposium on Advanced Wound Care, spring, May 2019, San Antonio TX USA, showed Lympha Press PCD-51 effective at healing chronic venous stasis ulcers (Mego Afek AC LTD.)

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the pressotherapy systems market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032.

The research study is based on the product – (system/pump, sleeves, and other accessories), and end user (medical spas, and specialty clinics), and across seven key regions of the world.

About FMI:

Cholesterol API Market size is expected to reach a valuation of US$ 269.0 Million by the end of 2022

[345 Pages Report] As per Future Market Insights’ latest industry analysis, the global cholesterol API market was valued at around US$ 258.4 Mn in 2021 and is projected to exhibit a CAGR of 4.7% over the forecast period (2022-2032). The global market is estimated to be valued at US$ 426.9 Mn in 2032.

Liposomes are a very important part of any drug delivery system with many beneficial properties such as easy preparation, bilayer structure assembling the cellular membrane, and high biocompatibility. Extensive efforts have been dedicated to the use of cholesterol in liposome-based formulations.

Cholesterol, being an integral part of any biological membrane, plays a significant role in liposomal formulations. Liposomes with higher cholesterol content are highly stable.

According to a study by Ascension Sciences published in December 2020, parameters like stability, size, and encapsulation efficiency are used during liposome formulation. Stability of a liposome formulation is greatly influenced by the amount of cholesterol present. A higher percentage of cholesterol favors the development of larger liposomes with less encapsulation effectiveness and higher drug retention.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15406

Despite various applications of liposomes, including diagnosis, food products, gene delivery, drug & vaccine delivery, and biosensor manufacturing, their use is severely constrained by their physicochemical instability. Cholesterol plays a crucial role in the stability of a liposomal membrane.

Moreover, cholesterol affects fluidity, drug retention, phospholipid packing, transition temperature (Tm), permeability, elasticity, membrane strength, and plasma stability. Researchers are set to use cholesterol as a promising substance for the stability of liposomes.

Owing to the aforementioned factors, the global cholesterol API market is set to gain traction over the forecast period.

Key Takeaways: Cholesterol API Market

By source, the animal-derived segment held approximately 7% of the cholesterol API market share in 2021 owing to their easy availability and low cost.
By manufacturing process, the GMP segment is set to generate a market share of around 9% by 2032.
By end user, the monoclonal antibodies segment is projected to grow at a CAGR of 0% during the forecast period.
East Asia cholesterol API market is expected to showcase the highest CAGR of 6% among all other regions from 2022 to 2032.
The U.S. cholesterol API market is anticipated to exhibit growth at a lucrative CAGR of 6% during the forecast period.

“Rising demand for RNA vaccines and monoclonal antibodies is projected to drive growth in the next decade. Besides, increasing use of liposomal formulations in drug delivery systems is set to propel sales of cholesterol APIs across the globe,” says an analyst of Future Market Insights.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15406

Competitive Landscape: Cholesterol API Market

The cholesterol API market is highly fragmented and it includes a variety of regional, start-up, and established companies. In order to increase their market share, key players are signing a large number of agreements and engaging in mergers & acquisitions, as well as collaborations.

For instance,

In May 2021, CordenPharma and the Otto-von-Guericke-University of Magdeburg, Germany developed a scalable synthesis of pharma-grade cholesterol which is used as part of the lipid cocktail for the assembly of effective mRNA-based vaccines.
In May 2020, Evonik announced €25m first stage of a new long-term program to support the high demand for contract manufacturing of APIs and advanced intermediates across Europe.

Get More Insights on Cholesterol API Market

Future Market Insights offers a unique perspective and actionable insights on the cholesterol API market in its latest study, presenting a historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.

The research study is based on the source (animal-derived, plant-derived, and synthetic), manufacturing process (GMP and non-GMP), and end user (RNA vaccines, monoclonal antibodies, and others) across seven key regions of the world.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15406

Cholesterol API Market Outlook by Category

By Source:

Animal Derived
Plant Derived
Synthetic

By Manufacturing Process:

GMP
Non – GMP

By End User:

RNA Vaccines
Monoclonal Antibodies
Others

About FMI:

Hemostasis Products Market is anticipated to secure US$ 1,580 Million in 2022

[307 Pages Report] The global hemostasis products market is estimated to garner US$ 2,638 Million while exhibiting a 5.3% CAGR during the forecast period. The growing support from several governments is likely to fuel the market growth in the coming years. The industry is expected to secure US$ 1,580 Million in 2022.

Data points	Key Statistics
Global Hemostasis Products Market CAGR (2022-to 2032)	5.3%
Global Hemostasis Products Market Size (2022)	US$ 1,580 Million
Global Hemostasis Products Market Size (2032)	US$ 2,638 Million

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15386

High-level technological advancements, strong economies, and a swarming pool of patients with a variety of blood disorders are the chief factors that will boost the market for hemostasis products in the near future. The leading causes of surgeries are cardiovascular disease and stroke, cancer, and injury. And any surgical procedure can develop severe complications and result in uncontrollable bleeding thus increasing the demand for hemostasis products.

The rapidly growing medical tourism sector coupled with the high investment made by governments of various countries towards the growth of the healthcare sector will provide lucrative opportunities for the growth of the market. The high expenses related to hemostasis products and stringent regulatory policies and the use of off-label products are projected to restrain the market’s growth over the forecast period.

The topical hemostasis product segment is likely to offer remunerative opportunities for the global hemostasis products market. Several emerging economies are making significant developments in their technological sector, thereby, providing lucrative opportunities to players in the market.

Key Takeaways:

The global hemostasis products market is estimated at USD 1,501 Million in 2021
By product, the topical hemostat segment accounts for a market share of 68.5% in 2021
By application, the myocardial infarction segment accounts for the highest market share of 19.5% during the forecasting period.
Market in the U.S to procure a market share of 29.5% during the assessment period.

“The increasing number of trauma and surgical cases, technological advancements in the fields of hemostasis products, and an increase in the prevalence of blood disorders are expected to fuel the demand for hemostasis products market over the forecast period”

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15386

Competitive Landscape

Key players in the global hemostasis products market are Medtronic, Johnson & Johnson, Baxter International, Pfizer, Becton, Dickinson, and Company (BD), B. Braun Melsungen AG, Tricol Biomedical, Hemostasis LLC, Teleflex Incorporated, CuraMedical BV, among various others

Recent updates from the industry are:

In July 2021- Baxter International Inc announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClotPolysaccharide Hemostatic System from CryoLife, Inc. The transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio across the hospital, including in the operating room. PerClot has a global commercial presence with sales in more than 35 countries worldwide.
Hemostasis is committed to producing high quality medical devices that are safe and effective for their intended use. Hemostasis introduced. BoneSeal bone hemostat is a new generation, absorbable solution providing immediate and long-term hemostasis without immediately dissolving. BoneSeal hemostat works quickly and delivers better results for you and your patients.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/15386

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global hemostasis products market presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Product (Topical hemostasis products, Infusible hemostasis products, Advanced hemostasis products) by Application (Trauma, Surgery, Hemophilia, Myocardial infarction, Others) and Region (North America, Europe, APAC, MEA, and Latin America)

About FMI: